Shenzhen Weiguang Biological Products Co Ltd (002880.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100002Q58

Price
19.78 CNY
Market cap
4.49 bn CNY
P/E (2025)
18.21
P/S (2025)
3.54
Dividend yield
1.01 %
Net margin
19.45 %
Return on equity (ROE)
10.21 %
Return on assets (ROA)
6.59 %

Shenzhen Weiguang Biological Products Co Ltd financials

Fiscal year20242025
Revenue1.20 bn CNY1.27 bn CNY
Gross profit503.87 m CNY498.61 m CNY
Operating income296.62 m CNY324.00 m CNY
EBIT319.60 m CNY303.91 m CNY
Net income253.52 m CNY246.32 m CNY
Diluted EPS – continuing operations1.12 CNY1.09 CNY

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Shenzhen Weiguang Biological Products Co Ltd

Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.